Xias Bio

Xias Bio

Biotechnology

Glasgow, Scotland 521 followers

Designing High-Performance Proteins to Empower Innovation and Sustainability

About us

At Xias Bio we utilise cutting-edge biotechnology and fermentation to supplant all animal-derived proteins. Our multi-functional proteins significantly outperform the status quo, align with regulation and consumer trends, and enable net zero goals. We envision a global adoption of our proteins, positioning Xias Bio as a global leader for sustainable multi-functional protein ingredients. Join us in catalysing the shift towards an eco-conscious and compassionate society, fostering positive change across industries

Website
https://www.xiasbio.com
Industry
Biotechnology
Company size
2-10 employees
Headquarters
Glasgow, Scotland
Type
Privately Held
Founded
2020

Locations

  • Primary

    90 Mitchell Street

    6th Floor Gordon Chambers

    Glasgow, Scotland G1 3NQ, GB

    Get directions

Employees at Xias Bio

Updates

  • Xias Bio reposted this

    View profile for Sean O'Sullivan, graphic

    Managing Partner, SOSV

    View profile for Stephen Chambers, graphic

    Managing Director at IndieBio NY & General Partner at SOSV

    Congrats to Xias Bio Limited, raising $3.6M investment. SOSV is proud to be your first VC check and join you on your journey.   Ever wondered why synthetic biology hasn't yet become the go-to for producing everyday chemicals and materials? The main hurdle isn't science—it's economics. Achieving large-scale production that competes cost-wise with traditional methods is a tough nut to crack. Banking on a "green premium"—the extra cost people might pay for eco-friendly products—sounds great, but it's not a reliable business plan. And assuming that larger production volumes will magically offset inefficient processes or expensive raw materials? That's another myth. To really make it in this field, even the greenest companies need a solid, scalable business model. Enter Xias Bio, producing animal-free ingredients for the cosmetic, food and pharmaceutical industries. They’ve nailed this challenge with breakthrough science and a business strategy that's both smart and sustainable. Think of them as the poster child for the new wave of synthetic biology companies. Instead of going head-to-head with industry giants, they’re partnering up with them, utilizing existing manufacturing capabilities, established market channels, and years of regulatory know-how.  This capital efficient model is readily recognised by biopharma startups, but somehow lost on the majority of synbio founders. This collaborative approach is not just strategic; it's necessary in today’s financial climate where traction & revenue is crucial for early-stage companies. Xias Bio’s platform isn't just a one-trick pony confined to the cosmetic industry. It's versatile, capable of churning out a variety of proteins and peptides. This flexibility means they can tap into multiple markets, responding to demand swiftly and efficiently. So, while the debate on the viability of biotech for mass production continues, companies like Xias Bio are already showing that with the right science & strategy, it’s not just possible—it’s essential.  Check out Founder David J. Harvey’s video to learn more about Xias Bio Limited Bio.

  • Xias Bio reposted this

    View profile for Stephen Chambers, graphic

    Managing Director at IndieBio NY & General Partner at SOSV

    Congrats to Xias Bio Limited, raising $3.6M investment. SOSV is proud to be your first VC check and join you on your journey.   Ever wondered why synthetic biology hasn't yet become the go-to for producing everyday chemicals and materials? The main hurdle isn't science—it's economics. Achieving large-scale production that competes cost-wise with traditional methods is a tough nut to crack. Banking on a "green premium"—the extra cost people might pay for eco-friendly products—sounds great, but it's not a reliable business plan. And assuming that larger production volumes will magically offset inefficient processes or expensive raw materials? That's another myth. To really make it in this field, even the greenest companies need a solid, scalable business model. Enter Xias Bio, producing animal-free ingredients for the cosmetic, food and pharmaceutical industries. They’ve nailed this challenge with breakthrough science and a business strategy that's both smart and sustainable. Think of them as the poster child for the new wave of synthetic biology companies. Instead of going head-to-head with industry giants, they’re partnering up with them, utilizing existing manufacturing capabilities, established market channels, and years of regulatory know-how.  This capital efficient model is readily recognised by biopharma startups, but somehow lost on the majority of synbio founders. This collaborative approach is not just strategic; it's necessary in today’s financial climate where traction & revenue is crucial for early-stage companies. Xias Bio’s platform isn't just a one-trick pony confined to the cosmetic industry. It's versatile, capable of churning out a variety of proteins and peptides. This flexibility means they can tap into multiple markets, responding to demand swiftly and efficiently. So, while the debate on the viability of biotech for mass production continues, companies like Xias Bio are already showing that with the right science & strategy, it’s not just possible—it’s essential.  Check out Founder David J. Harvey’s video to learn more about Xias Bio Limited Bio.

  • View organization page for Xias Bio, graphic

    521 followers

    A friendly rivalry of hair vs skincare-themed speaking sessions at SCS Annual Conference today. All great talks covering subjects like the role of emulsifiers in effectively delivering active ingredients, designing peptides which penetrate the skin to trigger protein production for skin repair and the importance of Tribology is studying hair fibre systems Looking forward to the upcoming student poster pitches and a day of talks tomorrow!

  • View organization page for Xias Bio, graphic

    521 followers

    Xias Bio are delighted to announce that we have raised £3.8 million Series Seed Funding to disrupt the protein-based ingredients market! This round was led by Happiness Capital | Certified B Corp, with participation from SOSV, Good Startup, CPT Capital and BoxOne Ventures. This investment will allow us to grow the team, streamline and accelerate operations, secure new opportunities in the cosmetics market and investigate other high-value applications within life science. Fully press release will available soon. Stay tuned for more info!

  • Xias Bio reposted this

    View organization page for Xias Bio, graphic

    521 followers

    The team here at Xias is growing! Delighted to welcome Jacob Canby and Liam Forbes to the Company, growing our R&D and lab capacity for making high-performance proteins, using sustainable methods. You will also catch our team at some events over the next few months, including: SCS Annual Conference, York in September IFSCC Congress, Brazil in October Beauty Connect, Los Angeles in October Please get in touch if you would like to meet with us at any of these events or would like to find out more about what we do at Xias!

    • No alternative text description for this image
  • View organization page for Xias Bio, graphic

    521 followers

    The team here at Xias is growing! Delighted to welcome Jacob Canby and Liam Forbes to the Company, growing our R&D and lab capacity for making high-performance proteins, using sustainable methods. You will also catch our team at some events over the next few months, including: SCS Annual Conference, York in September IFSCC Congress, Brazil in October Beauty Connect, Los Angeles in October Please get in touch if you would like to meet with us at any of these events or would like to find out more about what we do at Xias!

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

Xias Bio 2 total rounds

Last Round

Seed
See more info on crunchbase